EFFECT OF PERSONALIZED GENOMIC-GUIDED CHEMOTHERAPY REGIMENS ON TREATMENT OUTCOMES IN BRCA-MUTATED BREAST CANCER PATIENTS
- Authors
-
-
Ali Ahsan Mufti
Author
-
Abdul Sami Shaikh
Author
-
- Keywords:
- BRCA1, BRCA2, Chemotherapy, Genomic Medicine, Precision Oncology, Survival Analysis, Treatment Outcome
- Abstract
-
Background: BRCA1 and BRCA2 mutations confer a higher risk of breast cancer and influence tumor sensitivity to chemotherapeutic agents. Conventional chemotherapy protocols often overlook these genetic vulnerabilities, potentially limiting efficacy and increasing toxicity. Precision oncology offers the opportunity to tailor chemotherapy based on tumor genomic profiles to improve clinical outcomes.
Objective: To evaluate whether personalized genomic-guided chemotherapy regimens enhance treatment response, survival, and tolerability compared with standard chemotherapy in BRCA-mutated breast cancer patients.
Methods: A randomized controlled trial was managed with 110 BRCA-mutated breast cancer patients in South Punjab. Participants were randomly allocated to collect either genomic-guided personalized chemotherapy or standard chemotherapy. Tumor genomic profiling informed the selection of chemotherapeutic agents in the personalized arm. Primary conclusions included total response rate and progression-free survival, while secondary outcomes encompassed overall survival, toxicity profiles, and quality-of-life assessments. Statistics were evaluated using t-tests, chi-square tests, Kaplan–Meier survival analysis, and Cox proportional hazards modeling.
Results: The genomic-guided group demonstrated higher overall response rates (76.4% vs. 54.5%) and longer mean progression-free survival (18.6 ± 4.1 months vs. 14.2 ± 3.8 months) compared with the standard chemotherapy group. Overall survival at 18 months was 89.1% in the personalized group versus 72.7% in the standard arm. Grade III–IV toxicities were less frequent in the genomic-guided group (21.8% vs. 36.4%), and quality-of-life scores were higher (72.5 ± 8.4 vs. 64.7 ± 9.1).
Conclusion: Personalized genomic-guided chemotherapy improves treatment efficacy, reduces severe toxicities, and enhances quality of life in BRCA-mutated breast cancer patients. These findings support the integration of precision-guided chemotherapy into routine clinical practice to optimize therapeutic outcomes.
- Author Biographies
- References
-
1. Jamalinia M, Weiskirchen RJAoTM. Advances in personalized medicine: translating genomic insights into targeted therapies for cancer treatment. 2025;13(2):18.
2. Malgerud L. Advancing precision medicine in pancreatic cancer through bioinformatics-assisted genomic profiling and clinical stratification: Karolinska Institutet; 2025.
3. Emara HM, Allam NK, Youness RAJDO. A comprehensive review on targeted therapies for triple negative breast cancer: an evidence-based treatment guideline. 2025;16(1):1-31.
4. Zou Y, Zhang H, Chen P, Tang J, Yang S, Nicot C, et al. Clinical approaches to overcome PARP inhibitor resistance. 2025;24(1):156.
5. Pixberg C, Maurer C, Smetanay K, Straßl L, Hlevnjak M, Zapatka M, et al. COGNITION-GUIDE–Genomics-Guided Targeted Post-Neoadjuvant Therapy in Patients with Early Breast Cancer: Study Design of a Multicenter, Open-Label, Umbrella Phase II Study. 2025.
6. Sahu P. REPURPOSING METFORMIN WITH ELECTRICAL PULSES FOR TRIPLE-NEGATIVE BREAST CANCER APPLICATIONS: NOVEL IN-VITRO STUDIES: Purdue University Graduate School; 2025.
7. Thongkumkoon P, Sangphukieo A, Tongjai S, Noisagul P, Sangkhathat S, Laochareonsuk W, et al. Establishment, characterization, and genetic profiling of patient-derived osteosarcoma cells from a patient with retinoblastoma. 2024;14(1):11056.
8. Nusilati A. Detection of copy number aberrations in endometrial cancer using array CGH: Universitätsbibliothek Kiel; 2023.
9. Bollas A. Genome sequencing applications in precision medicine: From ancestry prediction to RNA variant calling: The Ohio State University; 2024.
10. Arun B, Couch FJ, Abraham J, Tung N, Fasching PAJBjoc. BRCA-mutated breast cancer: the unmet need, challenges and therapeutic benefits of genetic testing. 2024;131(9):1400-14.
11. Hussain A, Rahman S, Ramteke AS. Genomic Instability as a Therapeutic Target: Advancements from Experimental Research to Clinical Application. Molecular Targets in Cancer Therapy: Understanding Cellular Pathways for Therapeutic Interventions: Springer; 2025. p. 227-40.
12. Mastrodomenico L, Piombino C, Riccò B, Barbieri E, Venturelli M, Piacentini F, et al. Personalized systemic therapies in hereditary cancer syndromes. 2023;14(3):684.
13. Shah B, Hussain M, Seth AJCIiMB. Homologous Recombination Deficiency in Ovarian and Breast Cancers: Biomarkers, Diagnosis, and Treatment. 2025;47(8):638.
14. Chahat, Nainwal N, Murti Y, Yadav S, Rawat P, Dhiman S, et al. Advancements in targeting tumor suppressor genes (p53 and BRCA 1/2) in breast cancer therapy. 2025;29(3):2691-716.
15. Wang Y-W, Allen I, Funingana G, Tischkowitz M, Joko-Fru YWJBr. Predictive biomarkers for the efficacy of PARP inhibitors in ovarian cancer: an updated systematic review. 2025;3(1):14.
16. Board PCGE. BRCA1 and BRCA2: Cancer risks and management (PDQ®). PDQ Cancer Information Summaries [Internet]: National Cancer Institute (US); 2023.
17. Habaka M, Daly GR, Shinyanbola D, Alabdulrahman M, McGrath J, Dowling GP, et al. PARP Inhibitors in the Neoadjuvant Setting; A Comprehensive Overview of the Rationale for their Use, Past and Ongoing Clinical Trials. 2025:1-19.
- Cover Image
-
- Downloads
- Published
- 2025-02-28
- Section
- Articles
- License
-
Copyright (c) 2025 Ali Ahsan Mufti, Abdul Sami Shaikh (Author)
This work is licensed under a Creative Commons Attribution 4.0 International License.
